While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

A new drug is helping families who've spent years padlocking fridges, chaining garbage cans, and hiding food as their ...

Obesity, diabetes and cardiovascular diseases are increasingly present in the population. Brown adipose tissue has a ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.

Innovent completes first patient dosing in seventh phase 3 trial (GLORY-OSA) of mazdutide in China with moderate-to-severe OSA & obesity: San Francisco, US Tuesday, June 17, 2025, ...

Despite an increase in the prevalence of prescribing, only 0.5% of U.S. adolescents with obesity were prescribed an obesity ...

A new analysis of obesity guidelines suggests more evidence is needed to develop stronger guidelines for the transition ...

Adolescents face significant barriers to obesity medication access, despite a surge in prescriptions. Discover the ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

When pediatric health experts name the most worrisome medical conditions plaguing young people today, obesity often tops the list. According to global statistics from the World Health Organization, ...

0.5 percent with obesity were prescribed an obesity medication in 2023; 83 percent of prescriptions received by teens with severe obesity ...